Pre-existing antibodies to mycobacterial antigens

Pre-existing antibodies to mycobacterial antigens represent the baseline humoral immune state of an individual regarding Mycobacterium species prior to a specific medical intervention. These antibodies are often generated through exposure to environmental nontuberculous mycobacteria (NTM), previous Bacillus Calmette-Guérin (BCG) vaccination, or latent tuberculosis infection [PubMed: 24109141]. In clinical vaccinology, these antibodies are not traditional drug targets but act as significant modifiers of vaccine performance, potentially neutralizing viral vectors or masking epitopes on recombinant antigens [Journal of Infectious Diseases, 2013]. For instance, high levels of pre-existing anti-Ag85A antibodies have been associated with reduced immunogenicity of the MVA85A vaccine in clinical trials [Lancet, 2013]. They also serve as important biomarkers for diagnosing mycobacterial infections or assessing the risk of disease progression [Frontiers in Immunology, 2020]. Understanding these antibodies is crucial for the development of next-generation tuberculosis therapies and vaccines, as they can influence both safety profiles and the magnitude of the induced cellular immune response.

Other names

Anti-mycobacterial antibodiesPre-existing anti-TB antibodiesMycobacterial-specific immunoglobulinsBaseline mycobacterial antibodies

Pre-existing antibodies can modulate the immune response to mycobacterial vaccines through epitope masking, clearance of vaccine antigens, or antibody-dependent cellular cytotoxicity (ADCC) [PubMed: 24109141].